#USA #New York #Pomerantz LLP #Fortress Biotech #FBIO

Pomerantz Law Firm's Investigation into Fortress Biotech

In a recent development affecting investors of Fortress Biotech Inc. (NASDAQ: FBIO), the Pomerantz Law Firm has announced an investigation into potential securities fraud associated with the company. The announcement follows a notable plunge in Fortress’s stock price after recent regulatory news.

On October 1, 2025, Fortress Biotech disclosed receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application for CUTX-101. This letter indicated observed deficiencies concerning Current Good Manufacturing Practice (cGMP) at the manufacturing facility for CUTX-101. The company’s stock suffered significantly, falling by $1.14—approximately 30.81%—to end the day at $2.56 per share.

The Pomerantz Law Firm is urging people, particularly investors who may have been affected by these developments, to reach out to attorney Danielle Peyton for more information about joining the class action. The law firm, with offices in major cities including New York, Chicago, and Los Angeles, has a long-standing reputation in corporate litigation, especially in areas related to securities and antitrust class actions. Founded by the late Abraham L. Pomerantz, the firm pioneered the securities class action field more than 85 years ago and continues to advocate for the rights of investors.

Given the firm’s history of securing multimillion-dollar settlements for victims of securities fraud, the current investigation could yield significant insights into Fortress Biotech's recent challenges. Investors are concerned about the implications of the FDA's findings and whether the company, along with its directors and officers, may have engaged in misconduct or failed to adequately disclose material information, thereby endangering shareholder interests.

With a dedication to transparency and accountability in the market, Pomerantz is committed to holding companies to the highest standards, ensuring that investors are not unduly harmed by corporate missteps. The firm has successfully recovered substantial damages for many clients, a priority they aim to uphold through this ongoing investigation.

As the situation evolves, stakeholders in Fortress Biotech should stay informed about further developments and consider their options for legal recourse in light of this investigation. Contact information for interested parties has been provided by Pomerantz, as the firm looks to build a strong case on behalf of affected investors. This could be an important moment for those involved with Fortress Biotech to take action and ensure their voices are heard in this legal inquiry.

For anyone involved with Fortress, now is the time to assess the implications of recent events. Keeping abreast of legal options and actions will be crucial as the investigation unfolds and more details come to light. Fortress Biotech's recent challenges highlight the need for diligence and advocacy in the face of corporate oversight failures, ensuring that investors are protected and informed about their rights.

In summary, the Pomerantz investigation into Fortress Biotech could be pivotal for many investors who may have suffered losses due to the company's recent disclosures. As they prepare to pursue this case further, stakeholders should assemble relevant documentation and reach out to legal experts for guidance in navigating this situation effectively.